BNTX

96.90

0.05% 0.05

Handel nachbörslich: 96.90

Biontech Se Adr (BNTX)

Überblick Nachrichten Preisverlauf Optionskette Warum fällt BNTX? Forum Prognose Dividendenhistorie

Schlusskurs vom Vortag:

$96.85

Offen:

$97.35

24-Stunden-Volumen:

681.35K

Relative Volume:

0.60

Marktkapitalisierung:

$24.34B

Einnahmen:

$3.26B

Nettoeinkommen (Verlust:

$-1.45B

KGV:

-16.50

EPS:

-5.871

Netto-Cashflow:

$1.18B

1W Leistung:

-1.64%

1M Leistung:

-6.66%

6M Leistung:

+6.27%

1J Leistung:

-7.28%

1-Tages-Spanne:

$96.22

$98.00

1-Wochen-Bereich:

$96.22

$100.21

52-Wochen-Spanne:

$79.52

$124.00

Biontech Se Adr Stock (BNTX) Company Profile

Firmenname

Biontech Se Adr

Sektor

Healthcare (1064)

Branche

Biotechnology (595)

Telefon

Adresse

Mitarbeiter

7,807

Twitter

@BioNTech_Group

Nächster Verdiensttermin

2026-11-03

Neueste SEC-Einreichungen

BNTX's Discussions on Twitter

Compare BNTX vs VRTX, MRNA, REGN, ARGX, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BNTX Biontech Se Adr	96.90	24.75B	3.26B	-1.45B	1.18B	-5.871
VRTX Vertex Pharmaceuticals Inc	504.73	127.93B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	190.01	79.40B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	735.20	81.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.21	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	206.64	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Biontech Se Adr Stock (BNTX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-02	Herabstufung	Leerink Partners	Outperform → Market Perform
2026-01-16	Hochstufung	Goldman	Neutral → Buy
2025-06-05	Bestätigt	H.C. Wainwright	Buy
2025-05-29	Eingeleitet	Goldman	Neutral
2025-03-13	Eingeleitet	Citigroup	Buy
2025-01-10	Eingeleitet	Truist	Buy
2024-12-11	Eingeleitet	Wells Fargo	Overweight
2024-12-02	Bestätigt	BMO Capital Markets	Outperform
2024-11-19	Eingeleitet	Berenberg	Buy
2024-11-19	Hochstufung	Evercore ISI	In-line → Outperform
2024-11-08	Hochstufung	Goldman	Neutral → Buy
2024-09-24	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2024-09-17	Hochstufung	Jefferies	Hold → Buy
2024-09-16	Hochstufung	JP Morgan	Underweight → Neutral
2024-08-07	Hochstufung	Deutsche Bank	Hold → Buy
2024-08-02	Hochstufung	HSBC Securities	Hold → Buy
2024-05-14	Eingeleitet	Evercore ISI	In-line
2024-02-23	Eingeleitet	BMO Capital Markets	Outperform
2024-01-05	Eingeleitet	Oppenheimer	Perform
2023-12-01	Herabstufung	JP Morgan	Neutral → Underweight
2023-10-16	Herabstufung	HSBC Securities	Buy → Hold
2023-07-14	Eingeleitet	HSBC Securities	Buy
2023-05-17	Hochstufung	Redburn	Neutral → Buy
2022-12-15	Hochstufung	BofA Securities	Neutral → Buy
2022-08-17	Eingeleitet	Cowen	Market Perform
2022-07-13	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2022-07-06	Fortgesetzt	Canaccord Genuity	Buy
2022-02-01	Hochstufung	Redburn	Sell → Neutral
2021-12-16	Eingeleitet	Morgan Stanley	Equal-Weight
2021-11-10	Hochstufung	H.C. Wainwright	Neutral → Buy
2021-10-22	Eingeleitet	Deutsche Bank	Hold
2021-10-07	Eingeleitet	Jefferies	Hold
2021-08-11	Hochstufung	Bryan Garnier	Neutral → Buy
2021-07-19	Fortgesetzt	Wolfe Research	Outperform
2021-06-16	Herabstufung	Redburn	Neutral → Sell
2021-05-18	Eingeleitet	Goldman	Neutral
2021-05-11	Herabstufung	Bryan Garnier	Buy → Neutral
2020-12-01	Herabstufung	BofA Securities	Buy → Neutral
2020-08-03	Fortgesetzt	Berenberg	Buy
2020-07-21	Hochstufung	BofA Securities	Neutral → Buy
2020-06-30	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-05-19	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-04-28	Herabstufung	BofA/Merrill	Buy → Neutral
2020-03-18	Herabstufung	JP Morgan	Overweight → Neutral
2020-03-09	Eingeleitet	H.C. Wainwright	Neutral
2020-01-24	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2020-01-22	Herabstufung	UBS	Buy → Neutral
2019-11-05	Eingeleitet	Wolfe Research	Outperform
2019-11-04	Eingeleitet	Berenberg	Buy
2019-11-04	Eingeleitet	BofA/Merrill	Buy
2019-11-04	Eingeleitet	Canaccord Genuity	Buy
2019-11-04	Eingeleitet	JP Morgan	Overweight
2019-11-04	Eingeleitet	SVB Leerink	Outperform
2019-11-04	Eingeleitet	UBS	Buy

Alle ansehen

Biontech Se Adr Aktie (BNTX) Neueste Nachrichten

Oct 01, 2026

BioNTech CEO sells 39,000 shares. BioNTech stock has a USD 126.00 average target - AD HOC NEWS

Oct 01, 2026

BioNTech SE (BNTX) Stock Price, News, Quote & History - Yahoo! Finance Canada

Oct 01, 2026

Sep 30, 2026

Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now? - TradingView

Sep 30, 2026

Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast - GlobeNewswire Inc.

Sep 30, 2026

Sep 28, 2026

BioNTech SE (CEUX:22UAd)Valuation Measures & Financial Statistics - GuruFocus

Sep 28, 2026

BioNTech SE (BNTX) stock price, news, quote and history - Yahoo Finance Australia

Sep 28, 2026

Sep 27, 2026

BioNTech Balances Breakthrough Cancer Data Against a Messy Founder Split () - aktiencheck.de

Sep 27, 2026

Sep 25, 2026

BioNTech Steps Deeper Into Lung Cancer With New Dareon-Rosetta35 Trial - TipRanks

Sep 22, 2026

Sep 21, 2026

eBay Upgraded, Airbnb Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Sep 21, 2026

Sep 17, 2026

BioNTech CEO Sahin Ugur Sells 49,000 Shares, Retains 553,209 Shares Post-Transaction - Kalkine Media

Sep 17, 2026

Sep 14, 2026

"MarketWatch" Features Halberd Corporation With Prominent Pharmaceutical Companies on New Treatments for COVID-19 - ACCESS Newswire

Sep 14, 2026

BioNTech's lung cancer drug outperforms chemo in clinical study - mugglehead.com

Sep 14, 2026

Sep 12, 2026

BioNTech's Oncology Credibility Test Comes Down to Four Days in Seoul () - aktiencheck.de

Sep 12, 2026

Sep 09, 2026

Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit? - TradingView

Sep 09, 2026

BioNTech's Downsizing Signal: Factory Divestitures and a Trimmed Forecast Frame the Pipeline Debate - aktiencheck.de

Sep 09, 2026

Sep 08, 2026

Advanced Micro Devices Upgraded, Eli Lilly Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Sep 08, 2026

BioNTech CEO Ugur Sahin Executes Sale of 76,500 Shares Under Rule 10b5-1 Plan - Kalkine Media

Sep 08, 2026

Why Pfizer Stock Was so Healthy in August - The Motley Fool

Sep 08, 2026

This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday - Benzinga

Sep 08, 2026

Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

Sep 08, 2026

Why is BioNTech stock sliding today? - investing.com

Sep 08, 2026

Sep 06, 2026

BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development - Morningstar

Sep 06, 2026

BioNTech's Balancing Act: A COVID Lifeline Arrives Just as Oncology Investors Need a Reason to Stay - aktiencheck.de

Sep 06, 2026

Sep 04, 2026

PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last? - easternprogress.com

Sep 04, 2026

BioNTech's High-Stakes Seoul Debut: A Cash-Rich Pivot Meets Its First Real Test () - aktiencheck.de

Sep 04, 2026

BioNTech's September Test: Can Oncology Data Outweigh a Shrinking COVID Franchise? () - aktiencheck.de

Sep 04, 2026

Sep 03, 2026